Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9H936
UPID:
GHC1_HUMAN
Alternative names:
Glutamate/H(+) symporter 1; Solute carrier family 25 member 22
Alternative UPACC:
Q9H936; A8K366; C9J1H6; E9PJD3; E9PKB2; E9PL68; E9PN26; E9PNQ3; E9PP01; E9PR97; Q8TBU8
Background:
Mitochondrial glutamate carrier 1, also known as Glutamate/H(+) symporter 1 and Solute carrier family 25 member 22, plays a crucial role in transporting glutamate from the cytosol into the mitochondrial matrix. This process is vital for maintaining cellular energy balance and is linked to glucose-stimulated insulin secretion.
Therapeutic significance:
The protein is implicated in Developmental and epileptic encephalopathy 3 (DEE3), a severe form of epilepsy with no effective treatment. Understanding the role of Mitochondrial glutamate carrier 1 in DEE3 could pave the way for novel therapeutic strategies, potentially transforming patient outcomes.